Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
livin peptide-loaded dendritic cell + cytokine-induced killer cell therapy
- Development stage
- Unknown
- Lead developer
- Third Military Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Livin peptide-loaded dendritic cell + cytokine-induced killer cell (DC/CIK) therapy is an experimental autologous adoptive cellular immunotherapy. The therapy involves harvesting a patient's dendritic cells (DCs) and loading them with a peptide derived from Livin (BIRC7), a tumor-associated antigen and member of the inhibitor of apoptosis protein (IAP) family that is overexpressed in various malignancies, including non-small-cell lung cancer (NSCLC). These antigen-presenting cells are then combined with cytokine-induced killer (CIK) cells—a heterogeneous population of effector lymphocytes with potent non-MHC-restricted cytolytic activity—to stimulate a targeted immune response against Livin-expressing tumor cells. Primarily investigated in China by the Third Military Medical University, this therapy is typically evaluated in combination with radiotherapy or chemotherapy for patients with middle- or terminal-stage NSCLC to improve immune function and clinical efficacy.
- Other names
- DC/CIK therapy (Livin peptide-loaded)dendritic cell + cytokine-induced killer cell therapy (Livin peptide-loaded)
02
Targets
BIRC7
Beyond the preview
Go deeper on livin peptide-loaded dendritic cell + cytokine-induced killer cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on livin peptide-loaded dendritic cell + cytokine-induced killer cell therapy.